Chronic Kidney Disease – Epidemiology – Emerging Markets

Clarivate Epidemiology’s coverage of chronic kidney disease (CKD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of CKD for each country, as well as annualized case counts projected to the national population.

Patient populations are forecast over a period of 10 years for the emerging pharmaceutical markets covered in this content.

Clarivate Epidemiology’s CKD forecast will answer the following questions:

  • How many people with CKD are in each stage of the disease?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of CKD over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

Clarivate Epidemiology forecasts the following CKD patient populations:

  • Total prevalent cases of stage 1 CKD.
  • Total prevalent cases of stage 2 CKD.
  • Total prevalent cases of stage 3 CKD.
  • Total prevalent cases of stage 4 CKD.
  • Total prevalent cases of stage 5 CKD.
  • Total prevalent cases of dialysis-dependent stage 5 CKD.

Note: Coverage may vary by country and region.